Indivior PLC (NASDAQ:INDV) Given Average Recommendation of “Buy” by Analysts

Indivior PLC (NASDAQ:INDV) has received an average recommendation of “Buy” from the seven research firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $39.3333.

A number of equities analysts have issued reports on the stock. Northland Securities set a $50.00 price objective on shares of Indivior in a research note on Tuesday, January 20th. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 16th. HC Wainwright increased their price target on Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Morgan Stanley restated an “overweight” rating and issued a $36.00 price target on shares of Indivior in a research report on Wednesday, December 3rd. Finally, Weiss Ratings cut Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, March 17th.

Indivior Stock Down 3.3%

Shares of INDV stock opened at $28.97 on Friday. The stock has a 50-day moving average price of $32.80 and a 200 day moving average price of $31.00. The firm has a market cap of $3.62 billion, a price-to-earnings ratio of 17.66 and a beta of 0.83. Indivior has a 12 month low of $8.64 and a 12 month high of $38.00.

Indivior (NASDAQ:INDV) last released its earnings results on Friday, February 27th. The company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.17. The company had revenue of $358.00 million for the quarter, compared to the consensus estimate of $305.62 million. Indivior had a net margin of 16.85% and a negative return on equity of 148.76%. Sell-side analysts predict that Indivior will post 1.22 earnings per share for the current fiscal year.

Insider Transactions at Indivior

In related news, Director David E. Wheadon bought 1,771 shares of Indivior stock in a transaction on Monday, January 5th. The shares were purchased at an average price of $35.39 per share, for a total transaction of $62,675.69. Following the completion of the acquisition, the director owned 14,395 shares in the company, valued at approximately $509,439.05. This represents a 14.03% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Daniel A. Ninivaggi bought 775 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were bought at an average price of $35.39 per share, with a total value of $27,427.25. Following the completion of the transaction, the director directly owned 16,923 shares in the company, valued at approximately $598,904.97. This trade represents a 4.80% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have acquired 5,842 shares of company stock valued at $203,342.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd raised its holdings in Indivior by 72.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock worth $39,000 after purchasing an additional 460 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its position in shares of Indivior by 3.4% during the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 21,200 shares of the company’s stock worth $761,000 after purchasing an additional 700 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Indivior by 17.8% in the 4th quarter. Blue Trust Inc. now owns 4,859 shares of the company’s stock valued at $176,000 after buying an additional 733 shares during the period. Harbor Capital Advisors Inc. increased its position in shares of Indivior by 309.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after buying an additional 781 shares in the last quarter. Finally, Salomon & Ludwin LLC bought a new stake in shares of Indivior in the 4th quarter valued at $30,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.